Alamar Biosciences, Inc. (NASDAQ:ALMR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by Geri Gentry on Jul 26th, 2026

Shares of Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $30.00.

ALMR has been the subject of a number of recent research reports. Bank of America started coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They set a “neutral” rating and a $27.00 price objective for the company. Stifel Nicolaus began coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They issued a “buy” rating and a $28.00 target price on the stock. TD Cowen restated a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Zacks Research raised Alamar Biosciences to a “hold” rating in a report on Wednesday, May 13th. Finally, JPMorgan Chase & Co. initiated coverage on Alamar Biosciences in a research report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price target on the stock.

Get Our Latest Research Report on Alamar Biosciences

Alamar Biosciences Trading Down 0.0%

Alamar Biosciences stock opened at $25.88 on Friday. Alamar Biosciences has a 12 month low of $18.84 and a 12 month high of $29.43. The stock has a fifty day simple moving average of $23.21. The firm has a market capitalization of $1.79 billion and a P/E ratio of -14.87.

Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last issued its earnings results on Friday, May 8th. The company reported ($1.74) earnings per share for the quarter. The business had revenue of $26.04 million for the quarter.

Alamar Biosciences Company Profile

(Get Free Report)

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.

Alamar Biosciences, Inc. (NASDAQ:ALMR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Alamar Biosciences Trading Down 0.0%

Alamar Biosciences Company Profile

See Also

You might be interested in: